Search

everythinglearnresearchcommunity

for

Search:↓

Cross-sex hormone therapy is important for managing gender dysphoria and requires careful monitoring and healthcare provider education.

The document concludes that there are still unknowns about the effectiveness, risks, and detection of performance-enhancing drugs, and doping remains a challenge.

The conclusion is that certain surgeries can help people with gender dysphoria look more like their true gender and feel better.

In Japan, sex reassignment surgery for gender identity disorder faces challenges and needs better medical support and education.

Gender-affirming care greatly improves mental health for transgender and non-binary individuals.

Early medical support for transgender youth is important for their health, with low regret for gender-affirming hormone use and a need for knowledgeable care providers.

The document concludes that non-operative treatment for gender dysphoria is safe and effective, and hormone therapy does not increase cancer risk.

Young transgender, gender diverse, and nonbinary people on spironolactone have a low risk of high potassium, so frequent monitoring may not be needed.

Younger transgender women have surgery earlier, are mostly attracted to men, and show more preoperative depression that improves after surgery compared to older transgender women.

Women's hair grows faster and thicker than men's, but hair growth slows for both genders with pattern hair loss.

Transgender youth have more sleep disorders, but gender-affirming therapy may help reduce them.

Men and premenopausal women in Korea show different patterns in iron and vitamin D levels, with no clear pattern for postmenopausal women.

Gender differences affect allergy prevalence, severity, and response to environmental toxins, with women often more affected than men.

Gender-affirming hormone therapy improves mental health and gender incongruence but requires careful management of cardiovascular and cancer risks.

Ensure respectful and inclusive care for transgender and gender-diverse patients during surgery.

Gender affirming hormone therapy improves outcomes in gender affirmation surgery.

Most transgender adolescents continued hormone treatment, with few stopping due to reasons other than returning to their birth gender.

Gender-affirming care for youth remained essential during the COVID-19 pandemic, with telemedicine playing a key role.

AGA treatments like minoxidil and LLLLT are safe and effective for gender minority patients.

Women pay more for the same 5% minoxidil foam than men, but prices for liquid solutions are similar.

Men are more likely to have larger basal cell carcinomas and squamous cell carcinomas, while women have more superficial basal cell carcinomas and tumors on their legs and central face.

Transgender and nonbinary individuals experience hair loss, with transmen on testosterone seeing more severe hair loss, while feminizing hormones may stabilize hair loss in transwomen.

Male mice with FGF5 mutations grow longer hair than females.

The statement offers guidance for hormone therapy and surgery to help gender-incongruent adults affirm a male identity.

The guideline provides healthcare professionals in South Africa with instructions for comprehensive, multidisciplinary gender-affirming care, including HIV prevention and treatment for transgender and gender diverse individuals.

Gender-affirming hormone therapy in South Korea aligns with international guidelines and has specific side effects.

Women with pancreatic cancer are more likely to have certain side effects from chemotherapy than men.

Women who lost hair from childhood head radiation are more likely to face mental health issues than men.

Men and minority groups face higher risks and severe outcomes from SARS-CoV, MERS-CoV, and COVID-19.

Women's facial moisturizers cost more per ounce than men's.